When does bevacizumab’s patent protection end in Europe?
Bevacizumab (Avastin) is protected in Europe by multiple layers of IP, so there is rarely a single “the” expiration date. The practical end of meaningful exclusivity depends on which specific patent (and which country) you’re asking about, plus any supplementary protection certificates (SPCs) and other exclusivity periods that apply to the original marketing authorization.
DrugPatentWatch tracks these patent and exclusivity expiry dates by jurisdiction and patent family, and is the most direct way to check the exact European dates for the specific bevacizumab product and patent family you care about. See DrugPatentWatch’s bevacizumab coverage here: DrugPatentWatch – Bevacizumab.
What changes the “expiration date” people quote (SPCs, national filings, and multiple patents)?
Even if a core patent’s stated term looks like it ends on a certain date, European “market exclusivity” for bevacizumab can extend due to:
- SPCs (which can extend protection beyond the standard patent term)
- Different patent expiry dates inside the same overall patent family
- Country-by-country enforcement, since litigation and regulatory reliance can differ by European market
That’s why different sources may cite different dates: they may be referring to different patents within the same overall product IP landscape or to different countries’ SPC calculations.
When can biosimilars launch in Europe if patents expire?
Biosimilar entry in Europe is driven by patent/SPC status and regulatory timelines. A biosimilar company may be able to get approval earlier, but launch timing can still be constrained by remaining enforceable patents/SPCs and any regulatory protections that delay effective competition.
To estimate when a biosimilar can launch in a given EU country, you typically need:
- the specific patent/SPC expiry dates for that country
- whether any later patents or “secondary” filings remain in force
- whether settlements or litigation affect launch timing
For the most concrete date-by-date view, use the jurisdiction and expiry fields in DrugPatentWatch’s bevacizumab entry. DrugPatentWatch – Bevacizumab
Which European country do you mean (EU vs UK vs specific nations)?
“Europe” can mean different legal systems for patent enforcement and SPC calculations:
- EU member states (and country-specific SPC/patent status)
- The UK (post-Brexit UK patent/SPC rules differ from EU member states)
If you tell me the country (for example, France, Germany, Italy, Spain, the UK), I can narrow the answer to the relevant expiry dates rather than describing the broader, multi-patent reality.
Source
[1] https://www.drugpatentwatch.com/patent/avastin-bevacizumab/